Navigation Links
Study Reinforces Safety of Long-term Biologic Treatment for Rheumatoid Arthritis

A new study has emphasised the safety and efficacy of Enbrel (etanercept) in the long-term treatment of rheumatoid arthritis (RA) patients .

Biologics, such as etanercept, work by blocking the action of a naturally occurring protein in the body called tumour necrosis factor that is involved in causing inflammation. When combined with methotrexate, etanercept, also known as an anti-TNF therapy, etanercept has shown to halt radiographic damage in patients with moderate RA activity over multiple years, which means the disease is halted at that stage.

The study was conducted by a team of researchers at Wyeth Pharmaceuticals.

As part of the study, researchers analysed 2,054 patients receiving this biologic treatment for up to nine years by monitoring them for serious adverse events (SAEs), serious and opportunistic infections, sepsis, malignancies and lymphomas.

Researchers found that the overall rates of SAEs were similar to control groups (0.11 pt-yr and 0.17 pt/yr vs 0.11-0.20/pt yr), as were serious infections, and reports of opportunistic infection were rare, that means that there were improvements in disability whilst safety was also sustained over the long-term in the patients.

The study adds to the clinical evidence highlighting the role of prevention of disease progression through earlier anti-TNF treatment. Given the significant social and economical burden of this disease this makes good sense for patients and healthcare systems alike.

Enbrel has a well-characterized safety profile and is well tolerated. Although a rare event, a higher than expected rate of lymphoma was observed in the analysis. However, further study is required to establish whether this is related to TNF antagonist exposure or reflects the elevated risk of lymphoma in patients with RA.

These strong data should give doctors the confidence to consider a biologic earlier in patients with aggressi ve and progressive rheumatoid arthritis, and patients should now have the prospect of less disability with a treatment which has also proven to have a good long-term safety, Professor Lars Klareskog of Karolinska Institute Karolinska University Sweden, said.

Professor Emilio Martin Mola of the Rheumatology Unit at Hospital Universitario La Paz, Spain added: With both earlier and continuous use of Enbrel we can prevent the debilitating affects of RA taking hold and maintain this response for many years. Its critical that appropriate funding for biologics is sourced to continue the fight against serious inflammatory diseases, such as RA.

The findings of the study were presented at the EULAR (European League Against Rheumatism) congress.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... Texas (PRWEB) , ... January 24, 2017 , ... ... year introduces more changes during the Annual Enrollment Period (AEP) and the Open ... scrambling looking for health insurance coverage. Mainly, people are witnessing higher deductibles, rising ...
(Date:1/24/2017)... ... , ... The Cruise Web Inc. was recognized today as Northeast ... Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships Awards are ... on overall business growth in revenue and guests and continuous partnership support and innovative ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... solutions, announced that it has officially formed a distribution partnership with Byers ... the industrial odor management industry. , Through the agreement, OMI Industries formulated a ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing ... a new report from the Frank Hawkins Kenan Institute of Private Enterprise ... leaders, academics and policy makers identified concrete solutions at the “What’s Next, America?” ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date ... , Sharon Kleyne, the nation’s foremost water advocate and host of the ... Your Health on Voice America, once again welcomed one of her favorite guests ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- In a major study released this weekend from ... 1 ( http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/ ), Astute Medical,s ... patients at high risk of Acute Kidney Injury ... control trial led by Alexander Zarbock , ... standard of care or a treatment per Kidney ...
(Date:1/24/2017)... , Jan. 24, 2017 Market Research Future has a half ... Wound Closure Device is growing rapidly and expected to continue its growth ... ... CAGR of 5% from 2013 to 2019 and reaching a value of ... forecasted period, 2016-2022 Global Wound Closure Device Market has been ...
(Date:1/24/2017)... Jan. 24, 2017  The Orthopaedic Implant Company ... high-value orthopaedic implants, announced the launch of its ... The OIC Tibial Nail System is designed ... proximal and distal screw holes accommodate varying fracture ... dynamization.  The nail is available in diameters of ...
Breaking Medicine Technology: